Patent ID: 6641807
Filing Date: 2003-11-04
Classification: A61K,A61P,C07K,C12N

Abstract:
A method for delivering a therapeutic level of erythropoietin to a mammal in need thereof, the method comprising administering to the mammal a helper-dependent adenoviral vector which expresses erythropoietin, wherein the adenoviral vector has had the entire adenoviral genome coding sequence removed and substituted with exogenous stuffer DNA and DNA encoding erythropoietin operably linked to regulatory sequences for expression of erythropoietin, and wherein the adenoviral vector is administered in a dosage from about 1Ã—103 to 1Ã—106 adenoviral particles/g body weight of the mammal, and erythropoietin expression from the vector provides to the mammal at least 5 mU/ml circulating erythropoietin and an increase in haematocrit of at least 5%.